Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Press Releases
  Date Title View
Feb 14, 2005
OXiGENE's Lead Compound CA4P Enhances the Anti-Tumor Activity of Avastin in Pre-clinical Studies

Data Presented at International Symposium on Anti-Angiogenic Agents Conference in La JollaWALTHAM, Mass., Feb 14, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN) announced today that Dietmar Siemann, Ph.D., chairman of its scientific advisory boar...

Feb 9, 2005
OXiGENE Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2004 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 9, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's fourth quarter and full-year 2004 financial results conference call at 10:00 a.m. ET Friday, February 25, 2005. President and Chief Executive Officer Fred Driscoll, Chief Financial Office...

Feb 4, 2005
OXiGENE's CA4P Demonstrates Anti-tumor Activity in Preclinical Retinoblastoma Model- Study Published in Investigative Ophthalmology & Visual Science -

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 4, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today the publication of a preclinical study using local administration of Combretastatin A4P (CA4P) in the treatment of a murine model of retinoblastoma. The study reported that a subconjunctival delivery of CA4P, a vascular targeting agent (VTA)...

Jan 7, 2005
OXiGENE Announces Corporate Goals for 2005: Company Plans to Move CA4P into Later-stage Clinical Studies in Two Cancer Indications in 2005

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 7, 2005--OXiGENE, Inc. (Nasdaq: OXGN, XSSE: OXGN), developing novel small-molecule therapeutics to treat cancer and certain eye diseases, today announced its corporate goals for 2005. "We believe we are entering 2005 in th...

= add release to Briefcase